Ocrelizumab – Primary Progressive Multiple Sclerosis

Click here to receive MS news via e-mail


Ocrelizumab is a humanized monoclonal antibody currently under clinical investigation and development by the Swiss pharmaceutical company Roche. The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might be useful in normalizing the rates of immune attacks made by the host’s immune system against its own myelinated neurons, which form the main pathogenesis of multiple sclerosis (MS).

Read more: http://bit.ly/1JUBLqj

Tagged , .

Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.
Click here to receive MS news via e-mail


  1. JennyO says:

    My fiancee has PPMS and I would really love to know how to get him in this study! He is 34 and has 48% of his brain with lesions. His neurologist have told him soon he will “run out of brain” and die of PPMS. His doctor said he has the brain of a 65 year old , but in a 34 year old man

    Godspeed & God Bless you all 🙂


Leave a Comment

Your email address will not be published. Required fields are marked *